In a new study published in the Journal of the American Medical Association, a team of researchers found that a mineral water treatment can be used to help reduce toxins in the body.
They say the study shows that a combination of minerals can be helpful for reducing the levels of toxins found in the blood and body.
The team used the minerals calcium carbonate, magnesium sulphate, sodium carbonate and zinc sulfate in a liquid cleanser called “Molycorp”.
“What we found was that this treatment was able to remove all the contaminants and toxicants found in our bodies, as well as toxins from our blood,” said lead researcher Dr Jocelyn Hatton, from the University of Newcastle in Australia.
“This is important because if you’re getting toxins in your body, then your immune system is not functioning well.”
The research team, led by Dr Hatton and Dr Matthew Haddad from the Australian National University, also used the treatment to treat a small group of people who had a form of the hepatitis C virus.
“The hepatitis C patients were then given a standard hepatitis C drug called ZMapp,” Dr Haddart said.
“It is used to treat hepatitis C but also to treat other types of hepatitis C.”ZMapp can also be used for the treatment of other hepatitis C infections.””
They were given two weeks’ worth of treatment with ZMap and then followed up six weeks later to find out if they had recovered.
“In the study, which was carried out between December and March this year, the researchers tested patients for hepatitis C and other hepatitisC-related illnesses using the National Hepatitis C Surveillance System (NHCS) and the World Health Organization’s World Health Tracker.”
This study found that the combination of the minerals Molycorpy and ZMuprofen, as used in the treatment, was able, in some cases, to significantly lower hepatitisC antibody levels.””
We found that people who got treatment with this treatment had significantly lower levels of hepatitisC antibodies than those who didn’t.”
This study found that the combination of the minerals Molycorpy and ZMuprofen, as used in the treatment, was able, in some cases, to significantly lower hepatitisC antibody levels.
“In this study, we saw that a lot of people were actually doing better after they started taking this treatment,” Dr Zetkin said.
The results of the study have been presented at the Australian Liver Transplant Society’s 2017 Scientific Session and were published in JAMA Internal Medicine.
However, the study did not prove that the treatment worked for everyone.
“What you can do with this is if you get liver transplantation, you might need a different combination of therapies,” Dr Mark Brown from the National Liver Transplants Group at the University Health Network told News.net.au.
There are currently no drugs in development to combat hepatitis C, but Dr Brown said the new research could lead to a better understanding of how and why people who already have liver transplants have different levels of antibodies.
“For the people who do have a transplant and they’re not in a position to have liver transplant surgery, it might be helpful to use this combination,” Dr Brown explained.
“You don’t need surgery, you don’t have to use a lot more drugs, you can use this as an option to give you a liver transplant.”
Dr Hatton said while the treatment had potential, it was important to be careful about what treatment to use.
“If you are on a transplant or you are using this treatment as a way to treat your liver transplant, then you’re really making a big mistake,” she said.